The first clinical evidence to prove the involvement of inflammation in atherosclerotic disease was provided by the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial, clearly showing that treatment with a fully human monoclonal antibody targeting interleukin (IL)-1β reduced the cardiovascular disease risk in patients with old myocardial infarction (MI) [4]. Here, IL1B is linked to myocardial infarction.